

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

NMPA APPROVAL FOR REGISTRATION APPLICATION OF DCwire™ MICRO GUIDEWIRE

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on June 29, 2023, the Group received the approval from the National Medical Products Administration of the PRC (國家藥品監督管理局) (the “**NMPA**”) for the registration application of DCwire™ Micro Guidewire, making it the Group’s fifteenth NMPA approved neurointerventional product.

DCwire™ Micro Guidewire is a product developed by Achieva Medical Limited (“**Achieva**”), a wholly-owned subsidiary of the Company, and is designed based on the idea of “microstructure”. The term “microstructure” refers to the design of a multi-layered micro-structured device made of multiple materials through precision manufacturing. Due to the thin and tortuous nature of intracranial vessels, devices are required to be controlled and operated through tight spaces, and therefore, there is a heightened demand for precision with respect to the design and manufacturing of such devices. DCwire™ Micro Guidewire has realized the manufacturing precision as well as the unique material properties of “microstructure”, which allows the device to be precisely controlled and easy to super select vessels, enabling physicians build vascular access quickly and more easily during procedures.

DCwire™ Micro Guidewire is a new-generation neurointerventional micro guidewire developed by Achieva. NMPA approval for the registration application of DCwire™ Micro Guidewire is another significant step for the Company to enhance a well-rounded product portfolio for stroke treatment. We will continue to develop innovative products to help more patients maintain health and well-being.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET DCwire™ MICRO GUIDEWIRE SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, July 7, 2023

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip and Mr. Huacheng Wei as independent non-executive Directors.